Similarly, additionally to augment CD8+ T cell infiltration, the association of PARPi olaparib and PD-L1 blockade induced complete tumor regression in multiple immunocompetent small cell lung carcinoma (SCLC) mice models [133]. This evidence concerns the gene CD8A and small cell lung carcinoma.